Draupnir Bio is developing a new type of cholesterol-lowering medicine which prevents blood clots in the heart.
Draupnir Bio has raised $13.2M in total funding. The most recent round was Seed. The last funding was announced in July 2024.
Draupnir Bio's investors include HTGF (High-Tech Gruenderfonds), Novo Holdings, Inkef, Gilde Healthcare, Export and Investment Fund.
Draupnir Bio is headquartered in Risskov, Denmark.
Draupnir Bio is developing a new type of cholesterol-lowering medicine which prevents blood clots in the heart.
Draupnir Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Draupnir Bio — Funding & Investors." VCBacked, July 17, 2024, https://www.vcbacked.co/company/draupnir-bio. Accessed August 1, 2026.
VCBacked. (2024). Draupnir Bio — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/draupnir-bio
{{cite web |title=Draupnir Bio — Funding & Investors |url=https://www.vcbacked.co/company/draupnir-bio |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated